Skip to main content
Erschienen in: CEN Case Reports 1/2023

04.08.2022 | COVID-19 | Case Report

IgA vasculitis with transient glomerular hematuria, diarrhea, and pericarditis following COVID-19 mRNA vaccination in a young patient with possible pre-existing ulcerative colitis

verfasst von: Chiaki Ito, Kohei Odajima, Yoshiko Niimura, Misako Fujii, Masayuki Sone, Shinichiro Asakawa, Shigeyuki Arai, Osamu Yamazaki, Yoshifuru Tamura, Koji Saito, Yayoi Tada, Takatsugu Yamamoto, Ken Kozuma, Shigeru Shibata, Yoshihide Fujigaki

Erschienen in: CEN Case Reports | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Exacerbations or de novo autoimmune/autoinflammatory disease have been reported after COVID-19 vaccination. A young male presented with cutaneous IgA vasculitis with glomerular hematuria, diarrhea and pericarditis following his second COVID-19 mRNA vaccination. He also showed positivity for proteinase 3 anti-neutrophil cytoplasmic antibody (PR3-ANCA) and anti-cardiolipin antibody. Skin biopsy was compatible to IgA vasculitis. His purpura subsided and hematuria spontaneously disappeared. Treatment with anti-inflammatory medications and prednisolone resolved the pericarditis. He had a history of persistent diarrhea, and colonic biopsies showed possible ulcerative colitis without vasculitis. Kidney biopsy after prednisolone therapy revealed minor glomerular abnormalities without any immune reactants and did not show vasculitis. After prednisolone treatment, PR3-ANCA decreased in a medium degree despite of improvement of symptoms and inflammatory data, suggesting that his PR3-ANCA may be associated with ulcerative colitis. The cause of the transient glomerular hematuria was unclear, however, it might be caused by focal glomerular active lesions (glomerular vasculitis) due to vaccine-induced IgA vasculitis with nephritis. This case highlights that COVID-19 mRNA vaccination can activate multiple autoimmune/autoinflammatory systems. The conditions might help us better understand the mutual mechanisms of the relevant disorders.
Literatur
1.
Zurück zum Zitat Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med. 2009;360:1981–8.CrossRef Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med. 2009;360:1981–8.CrossRef
2.
Zurück zum Zitat Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, Haddad A, Elias M, Zisman D, Naffaa ME, Brodavka M, Cohen Y, Abu-Much A, Abu Elhija M, Bridgewood C, Langevitz P, McLorinan J, Bragazzi NL, Marzo-Ortega H, Lidar M, Calabrese C, Calabrese L, Vital E, Shoenfeld Y, Amital H, McGonagle D. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines (Basel). 2021;9:435.CrossRef Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N, Haddad A, Elias M, Zisman D, Naffaa ME, Brodavka M, Cohen Y, Abu-Much A, Abu Elhija M, Bridgewood C, Langevitz P, McLorinan J, Bragazzi NL, Marzo-Ortega H, Lidar M, Calabrese C, Calabrese L, Vital E, Shoenfeld Y, Amital H, McGonagle D. Immune-mediated disease flares or new-onset disease in 27 subjects following mRNA/DNA SARS-CoV-2 vaccination. Vaccines (Basel). 2021;9:435.CrossRef
3.
Zurück zum Zitat Chan ATP, Tang SCW. De novo and relapsing glomerulonephritis after COVID-19 vaccination: how much do we know? Nephrology (Carlton). 2022;27:5–6.CrossRef Chan ATP, Tang SCW. De novo and relapsing glomerulonephritis after COVID-19 vaccination: how much do we know? Nephrology (Carlton). 2022;27:5–6.CrossRef
4.
Zurück zum Zitat Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol. 2021;11: 617089.CrossRef Vojdani A, Vojdani E, Kharrazian D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol. 2021;11: 617089.CrossRef
5.
Zurück zum Zitat Hines AM, Murphy N, Mullin C, Barillas J, Barrientos JC. Henoch-Schönlein purpura presenting post-COVID-19 vaccination. Vaccine. 2021;39:4571–2.CrossRef Hines AM, Murphy N, Mullin C, Barillas J, Barrientos JC. Henoch-Schönlein purpura presenting post-COVID-19 vaccination. Vaccine. 2021;39:4571–2.CrossRef
6.
Zurück zum Zitat Naitlho A, Lahlou W, Bourial A, Rais H, Ismaili N, Abousahfa I, Belyamani L. A rare case of Henoch-Schönlein purpura following a COVID-19 vaccine-case report. SN Compr Clin Med. 2021;8:1–4. Naitlho A, Lahlou W, Bourial A, Rais H, Ismaili N, Abousahfa I, Belyamani L. A rare case of Henoch-Schönlein purpura following a COVID-19 vaccine-case report. SN Compr Clin Med. 2021;8:1–4.
7.
Zurück zum Zitat Sirufo MM, Raggiunti M, Magnanimi LM, Ginaldi L, De Martinis M. Henoch Schönlein purpura following the first dose of COVID-19 viral vector vaccine: a case report. Vaccines (Basel). 2021;9:1078.CrossRef Sirufo MM, Raggiunti M, Magnanimi LM, Ginaldi L, De Martinis M. Henoch Schönlein purpura following the first dose of COVID-19 viral vector vaccine: a case report. Vaccines (Basel). 2021;9:1078.CrossRef
8.
Zurück zum Zitat Obeid M, Fenwick C, Pantaleo G. Reactivation of IgA vasculitis after COVID-19 vaccination. Lancet Rheumatol. 2021;3: e617.CrossRef Obeid M, Fenwick C, Pantaleo G. Reactivation of IgA vasculitis after COVID-19 vaccination. Lancet Rheumatol. 2021;3: e617.CrossRef
9.
Zurück zum Zitat Kondo M, Yamanaka K. Possible HSP reactivation post-COVID-19 vaccination and booster. Clin Case Rep. 2021;9: e05032.CrossRef Kondo M, Yamanaka K. Possible HSP reactivation post-COVID-19 vaccination and booster. Clin Case Rep. 2021;9: e05032.CrossRef
10.
Zurück zum Zitat Mohamed MMB, Wickman TJ, Fogo AB, Velez JCQ. De novo immunoglobulin a vasculitis following exposure to SARS-CoV-2 immunization. Ochsner J. 2021;21:395–401.CrossRef Mohamed MMB, Wickman TJ, Fogo AB, Velez JCQ. De novo immunoglobulin a vasculitis following exposure to SARS-CoV-2 immunization. Ochsner J. 2021;21:395–401.CrossRef
11.
Zurück zum Zitat Badier L, Toledano A, Porel T, Dumond S, Jouglen J, Sailler L, Bagheri H, Moulis G, Lafaurie M. IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19. Autoimmun Rev. 2021;20: 102951.CrossRef Badier L, Toledano A, Porel T, Dumond S, Jouglen J, Sailler L, Bagheri H, Moulis G, Lafaurie M. IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19. Autoimmun Rev. 2021;20: 102951.CrossRef
12.
Zurück zum Zitat Maye JA, Chong HP, Rajagopal V, Petchey W. Reactivation of IgA vasculitis following COVID-19 vaccination. BMJ Case Rep. 2021;14: e247188.CrossRef Maye JA, Chong HP, Rajagopal V, Petchey W. Reactivation of IgA vasculitis following COVID-19 vaccination. BMJ Case Rep. 2021;14: e247188.CrossRef
14.
Zurück zum Zitat Iwata H, Kamiya K, Kado S, Nakaya T, Kawata H, Komine M, Ohtsuki M. Case of immunoglobulin A vasculitis following coronavirus disease 2019 vaccination. Dermatol. 2021;48:e598–9. Iwata H, Kamiya K, Kado S, Nakaya T, Kawata H, Komine M, Ohtsuki M. Case of immunoglobulin A vasculitis following coronavirus disease 2019 vaccination. Dermatol. 2021;48:e598–9.
15.
Zurück zum Zitat Nakatani S, Mori K, Morioka F, Hirata C, Tsuda A, Uedono H, Ishimura E, Tsuruta D, Emoto M. New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine: case report. CEN Case Rep. 2022;25:1–5. Nakatani S, Mori K, Morioka F, Hirata C, Tsuda A, Uedono H, Ishimura E, Tsuruta D, Emoto M. New-onset kidney biopsy-proven IgA vasculitis after receiving mRNA-1273 COVID-19 vaccine: case report. CEN Case Rep. 2022;25:1–5.
16.
Zurück zum Zitat Hashizume H, Ajima S, Ishikawa Y. Immunoglobulin A vasculitis post-severe acute respiratory syndrome coronavirus 2 vaccination and review of reported cases. J Dermatol. 2022;49:560–3.CrossRef Hashizume H, Ajima S, Ishikawa Y. Immunoglobulin A vasculitis post-severe acute respiratory syndrome coronavirus 2 vaccination and review of reported cases. J Dermatol. 2022;49:560–3.CrossRef
17.
Zurück zum Zitat Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, Kano T, Suzuki Y. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93:700–5.CrossRef Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, Kano T, Suzuki Y. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93:700–5.CrossRef
18.
Zurück zum Zitat Yamaji K, Suzuki Y, Suzuki H, Satake K, Horikoshi S, Novak J, Tomino Y. The kinetics of glomerular deposition of nephritogenic IgA. PLoS ONE. 2014;9: e113005.CrossRef Yamaji K, Suzuki Y, Suzuki H, Satake K, Horikoshi S, Novak J, Tomino Y. The kinetics of glomerular deposition of nephritogenic IgA. PLoS ONE. 2014;9: e113005.CrossRef
19.
Zurück zum Zitat Hotta O, Ieiri N, Nagai M, Tanaka A, Harabuchi Y. Role of palatine tonsil and epipharyngeal lymphoid tissue in the development of glomerular active lesions (glomerular vasculitis) in immunoglobulin A nephropathy. Int J Mol Sci. 2022;23:727.CrossRef Hotta O, Ieiri N, Nagai M, Tanaka A, Harabuchi Y. Role of palatine tonsil and epipharyngeal lymphoid tissue in the development of glomerular active lesions (glomerular vasculitis) in immunoglobulin A nephropathy. Int J Mol Sci. 2022;23:727.CrossRef
20.
Zurück zum Zitat Hana D, Patel K, Roman S, Gattas B, Sofka S. Clinical cardiovascular adverse events reported post-COVID-19 vaccination: are they a real risk? Curr Probl Cardiol. 2022;47: 101077.CrossRef Hana D, Patel K, Roman S, Gattas B, Sofka S. Clinical cardiovascular adverse events reported post-COVID-19 vaccination: are they a real risk? Curr Probl Cardiol. 2022;47: 101077.CrossRef
21.
Zurück zum Zitat Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305–53.CrossRef Matsuoka K, Kobayashi T, Ueno F, Matsui T, Hirai F, Inoue N, Kato J, Kobayashi K, Kobayashi K, Koganei K, Kunisaki R, Motoya S, Nagahori M, Nakase H, Omata F, Saruta M, Watanabe T, Tanaka T, Kanai T, Noguchi Y, Takahashi KI, Watanabe K, Hibi T, Suzuki Y, Watanabe M, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol. 2018;53:305–53.CrossRef
22.
Zurück zum Zitat Wang Y, Hsieh TC, Lee GY, Gorelick S, Maslak D. Ulcerative colitis flare-ups following mRNA COVID-19 vaccination. Am J Gastroenterology. 2021;116(SUPPL):S1029.CrossRef Wang Y, Hsieh TC, Lee GY, Gorelick S, Maslak D. Ulcerative colitis flare-ups following mRNA COVID-19 vaccination. Am J Gastroenterology. 2021;116(SUPPL):S1029.CrossRef
23.
Zurück zum Zitat Mahler M, Bogdanos DP, Pavlidis P, Fritzler MJ, Csernok E, Dam Oiseaux J, Bentow C, Shums Z, Forbes A, Norman GL. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta. 2013;424:267–73.CrossRef Mahler M, Bogdanos DP, Pavlidis P, Fritzler MJ, Csernok E, Dam Oiseaux J, Bentow C, Shums Z, Forbes A, Norman GL. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta. 2013;424:267–73.CrossRef
24.
Zurück zum Zitat Horn MP, Peter AM, Righini Grunder F, Leichtle AB, Spalinger J, Schibli S, Sokollik C. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn’s disease. PLoS ONE. 2018;13: e0208974.CrossRef Horn MP, Peter AM, Righini Grunder F, Leichtle AB, Spalinger J, Schibli S, Sokollik C. PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn’s disease. PLoS ONE. 2018;13: e0208974.CrossRef
25.
Zurück zum Zitat Chiarantini E, Valanzano R, Liotta AA, Cellai AP, Fedi S, Ilari I, Prisco D, Tonelli F, Abbate R. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res. 2019;82:137–46.CrossRef Chiarantini E, Valanzano R, Liotta AA, Cellai AP, Fedi S, Ilari I, Prisco D, Tonelli F, Abbate R. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res. 2019;82:137–46.CrossRef
26.
Zurück zum Zitat Koutroubakis IE, Petinaki E, Anagnostopoulou E, Kritikos H, Mouzas IA, Kouroumalis EA, Manousos ON. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 1998;43:2507–12.CrossRef Koutroubakis IE, Petinaki E, Anagnostopoulou E, Kritikos H, Mouzas IA, Kouroumalis EA, Manousos ON. Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. Dig Dis Sci. 1998;43:2507–12.CrossRef
27.
Zurück zum Zitat Talotta R, Robertson ES. Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: the straw that breaks the camel’s back? Cytokine Growth Factor Rev. 2021;60:52–60.CrossRef Talotta R, Robertson ES. Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: the straw that breaks the camel’s back? Cytokine Growth Factor Rev. 2021;60:52–60.CrossRef
28.
Zurück zum Zitat Donadio ME, Loiacono E, Peruzzi L, Amore A, Camilla R, Chiale F, Vergano L, Boido A, Conrieri M, Bianciotto M, Bosetti FM, Coppo R. Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch-Schönlein purpura and primary IgA nephropathy. Pediatr Nephrol. 2014;29:1545–51.CrossRef Donadio ME, Loiacono E, Peruzzi L, Amore A, Camilla R, Chiale F, Vergano L, Boido A, Conrieri M, Bianciotto M, Bosetti FM, Coppo R. Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch-Schönlein purpura and primary IgA nephropathy. Pediatr Nephrol. 2014;29:1545–51.CrossRef
30.
Zurück zum Zitat Dai W, Long L, Wang X, Li S, Xu H. Phytochemicals targeting Toll-like receptors 4 (TLR4) in inflammatory bowel disease. Chin Med. 2022;17:53.CrossRef Dai W, Long L, Wang X, Li S, Xu H. Phytochemicals targeting Toll-like receptors 4 (TLR4) in inflammatory bowel disease. Chin Med. 2022;17:53.CrossRef
Metadaten
Titel
IgA vasculitis with transient glomerular hematuria, diarrhea, and pericarditis following COVID-19 mRNA vaccination in a young patient with possible pre-existing ulcerative colitis
verfasst von
Chiaki Ito
Kohei Odajima
Yoshiko Niimura
Misako Fujii
Masayuki Sone
Shinichiro Asakawa
Shigeyuki Arai
Osamu Yamazaki
Yoshifuru Tamura
Koji Saito
Yayoi Tada
Takatsugu Yamamoto
Ken Kozuma
Shigeru Shibata
Yoshihide Fujigaki
Publikationsdatum
04.08.2022
Verlag
Springer Nature Singapore
Schlagwort
COVID-19
Erschienen in
CEN Case Reports / Ausgabe 1/2023
Elektronische ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-022-00727-w

Weitere Artikel der Ausgabe 1/2023

CEN Case Reports 1/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.